Skip to main content
. Author manuscript; available in PMC: 2012 Nov 15.
Published in final edited form as: Cancer Res. 2011 Oct 11;71(22):7080–7090. doi: 10.1158/0008-5472.CAN-11-2009

Figure 6. JO-1 improves cetuximab therapy in lung cancer xenograft models.

Figure 6

A) Subcutaneous A549 tumor model: JO-1 was injected at day 12 and 15 intravenously (2 mg/kg) or intraperitoneally (4 mg/kg) followed by an intraperitoneal injection of cetuximab or PBS 10 h later. One group received 1 mg/kg of JO-1 intravenously and 1 mg/kg intratumorally. n = 5. All JO-1 cotherapies are significantly more effective than trastuzumab alone. The difference between JO-1 injection routes was not significant. B) Mice received an intravenous injection of 2 mg/kg PtDd followed by an intraperitoneal injection of cetuximab (10 mg/kg) or PBS 10 h. A second treatment cycle was started at day 14 (marked by arrows). n = 5. Cetuximab vs. PtDd plus cetuximab P < 0.001. C) Metastatic A549 lung cancer model: 10 days after intravenous injection of A549 cells, mice received an intravenous injection of 2 mg/kg JO-1 or PBS, followed by an intraperitoneal injection of cetuximab (10 mg/kg) or PBS 10 h later. The treatment was repeated every 3 days until day 38. n=10. Left panels: Lungs from individual mice stained with India ink. Healthy tissue appears black. Tumor tissue stains white. Right panel: representative sections of lungs stained with H&E.